Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Sadif Analytics Prime
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

New Data For Novartis AG's Drug Lucentis Reinforces Transformational Efficacy And Well-Established Safety Profile Across Four Indications

Friday, 27 Sep 2013 01:16am EDT 

Novartis AG announced that new clinical and real world data for Lucentis (ranibizumab) presented in over 40 abstracts at this week's EURETINA congress confirm its transformational and well-established safety profile in four retinal diseases. Designed for intraocular use, Lucentis is an antibody fragment with a short systemic half-life and was first launched in Europe in 2007. Lucentis is now indicated in many countries for the treatment of wet age-related macular degeneration (wet AMD), for visual impairment due to diabetic macular edema (DME), macular edema secondary to branch- and central-retinal vein occlusion (BRVO and CRVO), and choroidal neovascularization secondary to pathologic myopia (myopic CNV). Lucentis study highlights at the 13th European Society of Retina Specialists (EURETINA) Congress in Hamburg, Germany include: Myopic CNV: In the RADIANCE global, Phase III, 12-month study, Lucentis was superior to current standard of care and improved mean visual acuity by around 14 letters at one year with a median of two injections 1. [Free paper session 6] In REPAIR, a Phase II, 12-month study, a mean visual acuity gain of 13.8 letters from a low number of injections to month 12 (mean 3.6, median 3) was demonstrated. Myopic CNV patients treated with Lucentis experienced high overall treatment satisfaction as measured using the Macular Disease Treatment Satisfaction Questionnaire. The overall score increased from 55.0 at month 1 to 64.9 at month 12 (p = 0.0001). 

Company Quote

30 Oct 2014